Literature DB >> 18413739

Breast carcinoma-associated fibroblasts and their counterparts display neoplastic-specific changes.

Nahed M Hawsawi1, Hazem Ghebeh, Siti-Faujiah Hendrayani, Asma Tulbah, Maha Al-Eid, Taher Al-Tweigeri, Dahish Ajarim, Ayodele Alaiya, Said Dermime, Abdelilah Aboussekhra.   

Abstract

It has become clear that the initiation and progression of carcinomas depend not only on alterations in epithelial cells, but also on changes in their microenvironment. To identify these changes, we have undertaken cellular and molecular characterization of carcinoma-associated fibroblasts (CAF) and their tumor counterpart fibroblasts (TCF) isolated from 12 breast cancer patients. Normal breast fibroblasts (NBF) from plastic surgery were used as normal control. We present evidence that both CAFs and TCFs are myofibroblasts and show tumor-associated features. Indeed, the p53/p21 response pathway to gamma-rays was defective in 70% CAFs, whereas it was normal in all the TCF and NBF cells. In addition, the basal levels of the p53 and p21 proteins were significantly low in 83% of CAFs and modulated in the majority of TCFs compared with NBFs. Interestingly, both TCFs and CAFs expressed high levels of the cancer marker survivin and consequently exhibited high resistance to cisplatin and UV light. Moreover, most CAFs were positive for the proliferation marker Ki-67 and exhibited high proliferation rate compared with NBFs and TCFs. However, proliferating cell nuclear antigen was highly expressed in both CAFs and TCFs. Using the two-dimensional gel electrophoresis technique, we have also shown that CAF, TCF, and NBF cells present different proteome profiles, with many proteins differentially expressed between these cells. Taken together these results indicate that different genetic alterations can occur in breast CAFs and their corresponding adjacent counterparts, showing the important role that stroma could play in breast carcinogenesis and treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18413739     DOI: 10.1158/0008-5472.CAN-08-0192

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  73 in total

1.  Senescent Breast Luminal Cells Promote Carcinogenesis through Interleukin-8-Dependent Activation of Stromal Fibroblasts.

Authors:  Huda H Al-Khalaf; Hazem Ghebeh; Rabia Inass; Abdelilah Aboussekhra
Journal:  Mol Cell Biol       Date:  2019-01-03       Impact factor: 4.272

2.  p16INK4A enhances the transcriptional and the apoptotic functions of p53 through DNA-dependent interaction.

Authors:  Huda H Al-Khalaf; Shreeram C Nallar; Dhananjaya V Kalvakolanu; Abdelilah Aboussekhra
Journal:  Mol Carcinog       Date:  2017-03-06       Impact factor: 4.784

Review 3.  Environment-mediated drug resistance: a major contributor to minimal residual disease.

Authors:  Mark B Meads; Robert A Gatenby; William S Dalton
Journal:  Nat Rev Cancer       Date:  2009-08-20       Impact factor: 60.716

Review 4.  Cancer stem cells, cancer cell plasticity and radiation therapy.

Authors:  Erina Vlashi; Frank Pajonk
Journal:  Semin Cancer Biol       Date:  2014-07-12       Impact factor: 15.707

Review 5.  The evolving relationship of wound healing and tumor stroma.

Authors:  Deshka S Foster; R Ellen Jones; Ryan C Ransom; Michael T Longaker; Jeffrey A Norton
Journal:  JCI Insight       Date:  2018-09-20

6.  The role of survivin in diagnosis, prognosis and treatment of breast cancer.

Authors:  Yong-Gang Lv; Fang Yu; Qing Yao; Jiang-Hao Chen; Ling Wang
Journal:  J Thorac Dis       Date:  2010-06       Impact factor: 2.895

Review 7.  Translational and basic science opportunities in palliative care and radiation oncology.

Authors:  Mai Anh Huynh; Alexander Spektor
Journal:  Ann Palliat Med       Date:  2019-07

Review 8.  Cancer-associated fibroblasts in hepatocellular carcinoma.

Authors:  Norio Kubo; Kenichiro Araki; Hiroyuki Kuwano; Ken Shirabe
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

9.  Genomics and proteomics approaches to the study of cancer-stroma interactions.

Authors:  Flávia C Rodrigues-Lisoni; Paulo Peitl; Alessandra Vidotto; Giovana M Polachini; José V Maniglia; Juliana Carmona-Raphe; Bianca R Cunha; Tiago Henrique; Caique F Souza; Rodrigo A P Teixeira; Erica E Fukuyama; Pedro Michaluart; Marcos B de Carvalho; Sonia M Oliani; Eloiza H Tajara; P M Cury; M B de Carvalho; E Dias-Neto; D L A Figueiredo; E E Fukuyama; J F Góis-Filho; A M Leopoldino; R C M Mamede; P Michaluart-Junior; R A Moyses; F G Nóbrega; M P Nóbrega; F D Nunes; E F B Ojopi; L N Serafini; P Severino; A M A Silva; W A Silva; N J F Silveira; S C O M Souza; E H Tajara; V Wünsch-Filho; A Amar; C M Bandeira; M A Braconi; L G Brandão; R M Brandão; A L Canto; M Cerione; R Cicco; M J Chagas; H Chedid; A Costa; B R Cunha; O A Curioni; C S Fortes; S A Franzi; A P Z Frizzera; D Gazito; P E M Guimarães; C M Kaneto; R V M López; R Macarenco; M R Magalhães; C Meneses; A M C Mercante; D G Pinheiro; G M Polachini; A Rapoport; C O Rodini; F C Rodrigues-Lisoni; R V Rodrigues; L Rossi; A R D Santos; M Santos; F Settani; F A M Silva; I T Silva; T B Souza; E Stabenow; J T Takamori; P J Valentim; A Vidotto; F C A Xavier; F Yamagushi; M L Cominato; P M S Correa; G S Mendes; R Paiva; O Ramos; C Silva; M J Silva; M V C Tarlá
Journal:  BMC Med Genomics       Date:  2010-05-04       Impact factor: 3.063

10.  Ecological therapy for cancer: defining tumors using an ecosystem paradigm suggests new opportunities for novel cancer treatments.

Authors:  Kenneth J Pienta; Natalie McGregor; Robert Axelrod; David E Axelrod
Journal:  Transl Oncol       Date:  2008-12       Impact factor: 4.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.